NYSEArca - Delayed Quote USD

Harbor Health Care ETF (MEDI)

25.27 -0.07 (-0.28%)
At close: 12:45 PM EDT
24.02 -1.25 (-4.96%)
After hours: 5:25 PM EDT
Loading Chart for MEDI
DELL
  • Previous Close 25.40
  • Open 25.29
  • Bid 12.62 x 1000
  • Ask 37.86 x 1000
  • Day's Range 25.27 - 25.27
  • 52 Week Range 20.73 - 27.48
  • Volume 627
  • Avg. Volume 7,022
  • Net Assets 10.18M
  • NAV 25.35
  • PE Ratio (TTM) 38.55
  • Yield 0.60%
  • YTD Daily Total Return 2.19%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.80%

The fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry (“health care companies”). It is non-diversified.

Harbor

Fund Family

Health

Fund Category

10.18M

Net Assets

2022-11-16

Inception Date

Performance Overview: MEDI

Trailing returns as of 4/18/2024. Category is Health.

YTD Return

MEDI
2.19%
Category
6.33%
 

1-Year Return

MEDI
22.07%
Category
11.04%
 

3-Year Return

MEDI
0.00%
Category
0.38%
 

People Also Watch

Holdings: MEDI

Top 10 Holdings (63.22% of Total Assets)

SymbolCompany% Assets
ASND
Ascendis Pharma A/S 16.22%
ABBV
AbbVie Inc. 9.87%
UNH
UnitedHealth Group Incorporated 6.96%
LLY
Eli Lilly and Company 6.84%
LEGN
Legend Biotech Corporation 5.71%
DXCM
DexCom, Inc. 4.14%
PFE
Pfizer Inc. 3.93%
OPCH
Option Care Health, Inc. 3.70%
LNTH
Lantheus Holdings, Inc. 2.94%
ICLR
ICON Public Limited Company 2.90%

Sector Weightings

SectorMEDI
Healthcare   98.36%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Related ETF News

Research Reports: MEDI

  • LGND: Lowering target price to $84.00

    LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • MYGN: Lowering target price to $20.00

    MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     
  • MYGN: Raising target price to $22.00

    MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     
  • LGND: Raising target price to $86.00

    LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     

Related Tickers